News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Pfizer Inc. (PFE)'s Arthritis Pill Tofacitinib Matches Abbott Laboratories (ABT)'s Humira in Final Studies


9/8/2011 7:03:59 AM

Pfizer Inc. (PFE)’s experimental pill for rheumatoid arthritis was as effective as Humira from Abbott Laboratories (ABT) and showed no new side effects in study results the company plans to submit for U.S. approval this year. Nine study summaries were released today and will be presented at the American College of Rheumatology conference in Chicago in November. In one trial, both doses of Pfizer’s drug, called tofacitinib, were slightly more effective than Humira across six categories of improvement in symptoms and patient mobility, though the study wasn’t big enough to establish the pill’s superiority.

Read at BioSpace.com
Read at Bloomberg
Read at Reuters

comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES